AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
197 hedge funds and large institutions have $2.18B invested in AMAG Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 73 increasing their positions, 51 reducing their positions, and 13 closing their positions.
338% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 13
60% more capital invested
Capital invested by funds: $1.36B → $2.18B (+$815M)
43% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 51
28% more funds holding
Funds holding: 154 → 197 (+43)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
62% less call options, than puts
Call options by funds: $1.16M | Put options by funds: $3.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$154M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$54.7M |
| 3 |
CI
Cambiar Investors
Denver,
Colorado
|
+$35M |
| 4 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$33.8M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$32.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$90.4M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$24.5M |
| 3 |
BC
Broadfin Capital
New York
|
-$24.4M |
| 4 |
AP
Alydar Partners
Boston,
Massachusetts
|
-$21.3M |
| 5 |
GCM
Greywolf Capital Management
Purchase,
New York
|
-$20.6M |
AMAG Hedge Fund Activity: Q1 2015 in Review
197 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q1 2015, worth a combined $2.18B — up 60% from $1.36B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new AMAG positions and 13 closed out — a net gain of 44 holders — while 73 added to existing stakes and 51 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $154M. The largest seller was Adage Capital Partners, cutting an estimated $90.4M.
- 197 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q1 2015, up from 154 in Q4 2014.
- Funds reported $2.18B of AMAG Pharmaceuticals stock for Q1 2015, up 60% quarter-over-quarter.
- 57 funds opened new AMAG Pharmaceuticals positions in Q1 2015 and 13 closed out, a net change of +44 holders.
- The largest AMAG Pharmaceuticals buyer in Q1 2015 was Fidelity Investments, an estimated $154M added.
- The largest AMAG Pharmaceuticals seller in Q1 2015 was Adage Capital Partners, an estimated $90.4M sold.
Based on aggregated 13F filings for Q1 2015.